Double transgenic neonatal porcine islets as an alternative source for beta cell replacement therapy
Proceedings of the National Academy of Sciences · 12.11.2024 · 121 (46)
DOI: 10.1073/pnas.2409138121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 04.11.2024. Verfasst von Nizar I Mourad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pôle de chirurgie expérimentale et transplantation, Université catholique de Louvain, Brussels 1200, Belgium. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Insulin-Secreting Cells, Insulin, Animals, Genetically Modified. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Service Public de Wallonie (SPW), EC | Seventh Framework Programme (FP7).
Abstract (Originalsprache)
To be clinically efficient, beta cell replacement therapies such as pig islet xenotransplantation must ensure sufficient insulin secretion from grafted islets. While protection from host immune reaction is essential for islet engraftment and their subsequent functioning, intrinsic physiological properties of used cells are also a key factor. We have previously shown that islets with adenoviral-mediated expression of a dipeptidyl peptidase-resistant form of glucagon-like-peptide-1 (GLP-1) and a constitutively activated form of type 3 muscarinic receptor (M3R) in their beta cells have greatly improved insulin secretory response to glucose stimulation that is otherwise 4 to 10 times lower than human islets. Here, we describe in vitro characterization of the secretory function of pancreatic islets, derived from transgenic pigs expressing the GLP-1M3R cassette under the porcine insulin promoter (InsGLP-1M3R), and their usage to treat insulin-dependent diabetes in an immunodeficient mouse model. Our results show that InsGLP-1M3R islets isolated from neonatal and adult pigs secrete up to 15-fold more insulin in response to glucose stimulation compared to wild-type (WT) islets. They also proved to be more efficient in treating diabetes in a preclinical model as shown by a significantly higher percentage of normoglycemic recipients and higher porcine C-peptide levels up to 9 mo post implantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pôle de chirurgie expérimentale et transplantation, Université catholique de Louvain, Brussels 1200, Belgium.
- Pig For Life, Marche-en-Famenne 6900, Belgium.
- Laboratorio di Tecnologie della Riproduzione, Avantea, Cremona 26100, Italy.
ORCID-Profile: Nizar I Mourad, Andrea Perota, Daela Xhema, Pierre Gianello
Förderung
- Service Public de Wallonie (SPW)
- EC | Seventh Framework Programme (FP7)
Zitieren
APA
Mourad, N. I., Perota, A., Xhema, D., Duchi, R., Lagutina, I., Galli, C., & Gianello, P. (2024). Double transgenic neonatal porcine islets as an alternative source for beta cell replacement therapy. Proceedings of the National Academy of Sciences, 121(46). https://doi.org/10.1073/pnas.2409138121
Vancouver
Mourad NI, Perota A, Xhema D, Duchi R, Lagutina I, Galli C, et al. Double transgenic neonatal porcine islets as an alternative source for beta cell replacement therapy. Proceedings of the National Academy of Sciences. 2024;121(46). doi:10.1073/pnas.2409138121
BibTeX
@article{Mourad2024,
author = {Mourad, Nizar I and Perota, Andrea and Xhema, Daela and Duchi, Roberto and Lagutina, Irina and Galli, Cesare and Gianello, Pierre},
title = {Double transgenic neonatal porcine islets as an alternative source for beta cell replacement therapy},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {46},
doi = {10.1073/pnas.2409138121}
}
EUVIMED